
Sign up to save your podcasts
Or


Business, when it’s at its best, can solve very big problems. And today Leadership Next is talking about a very big problem - COVID-19.
George Yancopoulos is the President and Chief Scientific Officer of Regeneron. His company announced this week it has developed a promising drug to fight coronavirus, and will begin human trials by early summer.
Yancopoulos details the innovative approach Regeneron used to create the drug - an approach that led to an effective therapy for Ebola.
He also explains that a Regeneron drug aimed at patients with rheumatoid arthritis is currently being used to treat some of the worst symptoms of COVID-19. The treatment is still in a trial phase but, if successful, could potentially keep severely ill patients off of ventilators.
Leadership Next host Alan Murray told Yancopoulos, “This is the most encouraging conversation I’ve had in quite awhile.”
By Fortune4.5
100100 ratings
Business, when it’s at its best, can solve very big problems. And today Leadership Next is talking about a very big problem - COVID-19.
George Yancopoulos is the President and Chief Scientific Officer of Regeneron. His company announced this week it has developed a promising drug to fight coronavirus, and will begin human trials by early summer.
Yancopoulos details the innovative approach Regeneron used to create the drug - an approach that led to an effective therapy for Ebola.
He also explains that a Regeneron drug aimed at patients with rheumatoid arthritis is currently being used to treat some of the worst symptoms of COVID-19. The treatment is still in a trial phase but, if successful, could potentially keep severely ill patients off of ventilators.
Leadership Next host Alan Murray told Yancopoulos, “This is the most encouraging conversation I’ve had in quite awhile.”

1,720 Listeners

4,423 Listeners

2,171 Listeners

1,993 Listeners

436 Listeners

2,686 Listeners

3,986 Listeners

581 Listeners

194 Listeners

173 Listeners

6,108 Listeners

1,578 Listeners

154 Listeners

190 Listeners

88 Listeners